Introduction {#Sec1}
============

The prevalence of obesity is rapidly increasing in Australia, from 44% of adults with overweight or obesity in 1989, to 63% in 2012 \[[@CR1]\]. In 2013, the National Health and Medical Research Council (NHMRC) released revised guidelines for the management of individuals with overweight and obesity for all primary health care professionals \[[@CR2]\]. There are currently no published data indicating the level of pragmatic use of these guidelines in the targeted professional groups. This article does not directly report the results of any trials involving human or animal subjects.

Barriers to Management of Obesity {#Sec2}
=================================

As general practice is the primary point of contact for most people seeking health services \[[@CR3]\], this would seem to be an ideal setting to initiate overweight and obesity management. However, a retrospective analysis of general practice data from Melbourne showed that only 22.2% of adults had their body mass index (BMI) recorded, and only 4.3% had a recorded waist circumference \[[@CR4]\]. In addition, the general practitioner (GP) management rate of obesity remained unchanged, at about 0.7 per 100 encounters \[[@CR5]\]. A study from the USA showed that, while less than 20% of 2543 individuals with obesity had a documented diagnosis, physicians were more likely to formulate a treatment plan in individuals with a formal diagnosis \[[@CR6]\].

Making It Work in General Practice {#Sec3}
==================================

In this review, we propose a pragmatic, patient-centered and consult-based four-step approach to obesity management in primary care.

An important step in obesity management in primary care should be to increase obesity awareness and upskill GPs on the latest evidence-based effective therapies to overcome physician-based inertia. Such obesity-focused education would allow for the development of pragmatic and structured clinical pathways, taking into account available local resources. The stepwise process below should support clinicians and patients' making individualized choices of what may effectively assist self-management of obesity and complications.

Step One: Baseline Assessment (Preparatory Consultations 1 and 2) {#Sec4}
=================================================================

Identification of Individuals with Obesity {#Sec5}
------------------------------------------

All clinical staff should utilize existing chronic disease management systems to serially record measures of weight, height, waist circumference, and BMI.BMI is considered the most useful population-level measure of overweight and obesity \[[@CR7]\], although known ethnic variations occur \[[@CR8]\]. Waist circumference also provides a measure of visceral adiposity (Table [1](#Tab1){ref-type="table"}).Table 1Definition of disease risk in adults by WHO BMI classification and waist circumference thresholds.© 2017 WHO, reproduced with permission from [http://apps.who.int/bmi/index.jsp?introPage=intro_3.html](http://apps.who.int/bmi/index.jsp%3fintroPage%3dintro_3.html)ClassificationBMI cutoff\
points (kg/m^2^)BMI cutoff points for\
Asian ethnicity (kg/m^2^)Disease risk relative to normal weight for waist circumference cutoff pointsMen: 94--102 cm\
Women: 80--88 cmMen: \> 102 cm\
Women: \> 88 cmNormal weight18.5--24.918.5--22.9Overweight25.0--29.9≥ 23.0IncreasedHighObesity class I30.0--34.927.5--32.4HighVery highObesity class II35.0--39.932.5--37.4Very highVery highObesity class III≥ 40.0≥ 37.5Extremely highExtremely highDevelop and maintain practice-wide systems focused on patient risk identification.

Risks of Obesity-Related Complications {#Sec6}
--------------------------------------

Once identified, further assessment of an individual with overweight or obesity may involve:Engaging individuals at risk: gaining "permission" to discuss obesity and its consequences.Focused history: evaluation of diet, previous and current physical activity, sleep and psychological assessment.Physical examination (e.g., cardiovascular measures): apply risk assessment such as the Australian type 2 diabetes risk assessment tool \[[@CR9]\] and the Australian absolute cardiovascular disease risk calculator \[[@CR10]\].Apply clinical staging of the patient's condition using clinical tools such as the Edmonton scale \[[@CR11]\] (Fig. [1](#Fig1){ref-type="fig"}), incorporating anthropometry and obesity complications assessment, to focus management.Specific focused investigations appropriate for any identified risks or complications.Medications review: consider suitable alternatives if current medications are known to cause weight gain.Fig. 1The Edmonton scale.Reproduced with permission from <http://www.drsharma.ca>

Step Two: Advice, Support, and Therapy (Review Consultations 3 and 4) {#Sec7}
=====================================================================

Explore the patient's understanding of the causes and management of overweight and obesity. Elaborate on the health benefits of weight loss \[[@CR12]\].Advise that this is a chronic, often progressive, lifelong health condition.Collaborate on setting SMART goals \[(S)pecific, (M)easurable, (A)ssignable, (R)ealistic, (T)ime-related\].Utilize existing chronic disease management systems including practice staff and nurses, computer databases, and review systems to manage patient support.Make efforts to individualize treatment for the patient. Focus should be on an improvement in weight-related complications, physical function, cardiovascular fitness, and/or quality of life (Table [2](#Tab2){ref-type="table"}) \[[@CR13]\].Explain the multimodal team-based management of obesity, including input from external specialists such as an exercise physiologist, dietitian, psychologist, and practice nurse, and how each team member can assist \[[@CR14]\]. Team-based members may be assigned according to identified needs (Fig. [2](#Fig2){ref-type="fig"}).Make timely contact (e.g., 2 weeks after commencing assessment) to determine individual engagement, review investigations, and adjust goals if necessary, so that goals can be realistically met.Discuss economic factors (both patient and local health service provision) that influence treatment choice and availability of team-based resources. Table 2Management of individuals with obesity in Australian primary care \[[@CR13]\]Obesity needs to be treated with empathy and without prejudiceObesity is associated with increased risks of serious comorbiditiesObesity significantly affects quality of life and reduces average life expectancyEffective treatment of obesity should address both the medical and social burden of diseaseObesity needs to be treated within the health care system as any other complex diseaseObesity management is a lifelong task given that at present no cure existsCalorie reduction, increased physical activity, and other lifestyle modifications are essential foundations upon which other therapies can be builtRealistic goals should be setAnti-obesity pharmacotherapy can facilitate weight lossReferral to specialist metabolic obesity services may be appropriate for selected patients Fig. 2Model for multimodal obesity management

Therapeutic Options {#Sec8}
-------------------

### Role of Very-Low-Energy Diets (VLED) {#Sec9}

A VLED can be considered as an initial weight-loss strategy, when supervised lifestyle interventions alone have not resulted in sufficient weight loss or comorbidity improvement, or when rapid weight loss is required (e.g., prior to metabolic (previously known as bariatric) or general surgery that is conditional on weight loss) either alone or in combination with pharmacotherapy. A VLED involves three meal replacements equating to less than 3300 kJ/day (800 kcal/day). VLEDs are low in carbohydrates, inducing mild ketosis after 2--3 days, once the body's glycogen stores have been fully utilized, which subsequently has an anorexic effect.

### Role of Pharmacotherapy {#Sec10}

The adoption of healthy lifestyle habits is the foundation to managing obesity; however, for many individuals, additional intensive interventions are required. In Australia, three pharmacotherapeutic agents are approved for use in weight management---loss and prevention of regain: phentermine, orlistat, and liraglutide.

Phentermine is a centrally acting adrenergic agonist that suppresses appetite and is approved for use adjunct to dietary management of obesity. Phentermine is registered for use as a short-term therapy, and it is recommended that a review is carried out after 3 months, as long-term safety has not yet been tested. Orlistat---available at higher doses with prescription, or at lower doses over-the-counter---inhibits pancreatic and gastric lipase, reducing fat absorption by approximately 30% \[[@CR15]\]. Liraglutide 3.0 mg is a centrally acting glucagon-like peptide-1 receptor agonist that is available as a once-daily subcutaneous long-term therapy for weight both weight loss and weight maintenance.

As obesity is a long-term chronic disease, health care practitioners should consider the use of long-term medication to both assist with weight loss or to prevent further weight regain. When judging the benefits of pharmacotherapy versus the risks, health care professionals should consider factors including improved control of eating behavior including reduced cravings, quality of life improvements, weight-loss maintenance in addition to weight-loss benefits.

Step Three: Referral Using Treatment Algorithm (Review Consultations 5--8) {#Sec11}
==========================================================================

Either commence supervised lifestyle interventions (including allied health such as psychologists, exercise physiologists, and dietitians) and arrange follow-up visits;orFacilitate referral to a specialist team (metabolic obesity clinic and/or metabolic surgery clinic) if:Patient is unable to achieve \> 5% weight loss at 3 months on a lifestyle intervention adjunct to a reduced-energy/low-energy diet, increased physical activity, and/or pharmacotherapy (see "[Stopping Rule](#Sec12){ref-type="sec"}").Patient is advancing Edmonton stages (in the Edmonton obesity staging system \[[@CR11]\]) despite medical therapy intervention.

Prioritize referral of individuals with a BMI ≥ 40 kg/m^2^ or BMI \> 35 kg/m^2^ with at least one weight-related comorbidity to bariatric surgical services.

The Australian and New Zealand Obesity Society (ANZOS) has recently published an Australian obesity management algorithm (Fig. [3](#Fig3){ref-type="fig"}) developed by a working group with representatives from the Australian Diabetes Society, ANZOS, and the Obesity Surgery Society of Australia & New Zealand \[[@CR16]\].Fig. 3The Australian obesity management algorithm\* Previously known as bariatric surgery© 2016 ANZOS, reproduced with permission from <http://anzos.com/assets/Obesity-Management-Algorithm-18.10.2016.pdf>

Stopping Rule {#Sec12}
-------------

Anti-obesity pharmacotherapy should be continued beyond 12 weeks*only* if at least 5% of initial body weight has been lost since starting medication. Therapy should then be continued for as long as there are clinical benefits, including*prevention* of significant weight regain. Continuing risks and benefits should be regularly reviewed and discussed \[[@CR17]\].

Step Four: Revision and Re-evaluation (Review Consultations 9+) {#Sec13}
===============================================================

Prevention of Weight Regain {#Sec14}
---------------------------

Consider discussing the use, or reintroduction, of structured intensive programs (including meal replacement, high-protein diets, and anti-obesity pharmacotherapy) shown to improve chances of maintaining weight loss \[[@CR18]\].Individuals need to be educated that the body physiologically defends against weight loss \[[@CR19]\]. Help the individual develop an "action plan", for example, what to do if they regain 3 kg or more \[[@CR17]\].

In the Absence of Complications/Comorbidities {#Sec15}
---------------------------------------------

If initial weight loss and health improvement goals are achieved, negotiate and create a subsequent plan focusing on strategies for weight maintenance and prevention of weight-related comorbidities \[[@CR20]\].Regularly (e.g., every 8 weeks) monitor and re-evaluate agreed goals including investigations where appropriate.

Co-Existing Complications/Comorbidities and Metabolic Surgery Patients {#Sec16}
----------------------------------------------------------------------

Re-evaluate weight management goals.Assess and manage adverse effects of weight loss interventions, or changing/emerging comorbidities (e.g., medication dose adjustment) and individual needs (e.g., pregnancy, ageing, etc.).Support ongoing communication with, and engagement in, specialist team-based care.Clinically assess and monitor metabolic and nutritional parameters.

Role of Metabolic Surgery {#Sec17}
-------------------------

Metabolic surgery has been shown to be the most effective treatment modality producing a significant and sustainable weight loss (20--35% of starting weight) and provides important benefits for more serious comorbidities \[[@CR21]\]. Metabolic surgery should be viewed as a therapeutic tool, and eligible patients need to be carefully selected and supported. Given that, at present, a cure for obesity does not exist, patients will still require lifelong follow-up by both their GP and metabolic surgery clinic. Therefore, GPs should encourage all patients who have had metabolic surgery to be reviewed annually by the surgical team, and more often if clinically indicated. Women are advised to use regular effective contraception and avoid getting pregnant for at least 12 months post-surgery. They should also notify their metabolic surgery clinic prior to considering starting a family or as soon as they find out they are pregnant, for ongoing specialist support.

Weight Loss in the Elderly (≥ 65 Years) {#Sec18}
---------------------------------------

There is a higher risk of obesity-related comorbidities with ageing; however, there is no clear BMI target in this age group. The main goal in older adults with obesity is to improve physical function, balance, and cardiovascular fitness, and minimize both sarcopenia and the impact of obesity-related complications \[[@CR22]\]. Use of metabolic surgery as a primary treatment of obesity in older adults (≥ 65 years) is decided on a case-by-case basis.

Final Thoughts {#Sec19}
==============

Obesity is a chronic health condition requiring long-term treatment and management. General practitioners have a key role in identifying individuals with or at risk of obesity; implementing appropriate interventions to support weight loss or maintenance; and/or the prevention of weight re-gain. Primary health care practitioners could facilitate patients' access to obesity support services that can provide the level of treatment required for the psychosocial complexities associated with obesity.

General practices can strategically improve services for these patients and carers through individual GP education, education of practice staff, the development of obesity-focused practice resources (including a referral network of specialist services), and a multidisciplinary team. Ultimately, reducing discrimination will help embed anti-obesity services in our health systems.
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